Concepedia

Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive Fibromatosis

Stefano Signoroni, Milo Frattini, Tiziana Negri, Elisa Pastore, Elena Tamborini, Paola Casieri, Marta Orsenigo, Luca Riva, Paolo Radice, Paola Sala,

Clinical Cancer Research · 2007 · 90 citations · 14 references

DOIFull text

Open access

Abstract

Aggressive fibromatosis is characterized by WNT/oncogene pathway alterations triggering COX-2-mediated constitutive coactivation of PDGFRA and PDGFRB, and may therefore benefit from combined nonsteroidal anti-inflammatory drug + tyrosine kinase inhibitor treatment.

References

14

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Kenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 176.9K citations

, , +12

Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC

Patrice J. Morin, Andrew B. Sparks, Vladimír Kořínek et al. · Science · 1997 · 3.9K citations

Molecular pathology of cyclooxygenase-2 in neoplasia.

E Fosslien · PubMed · 2000 · 400 citations

, , +17

Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)

Sabine Tejpar, Friedel Nollet, Catherine Li et al. · Oncogene · 1999 · 345 citations

, , +7

Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)

Michael C. Heinrich, Grant A. McArthur, George D. Demetri et al. · Journal of Clinical Oncology · 2006 · 315 citations